Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano,Hans Curigliano,Nicolas Mach,Toshihiko Doi,David Tai,Patrick M. Forde,John Sarantopoulos,Philippe L. Bedard,Chia-Chi Lin,F. Stephen Hodi,Sofie Wilgenhof,Armando Santoro,Catherine A. Sabatos-Peyton,Tyler A. Longmire,Alexandros Xyrafas,Haiying Sun,Sabine Gutzwiller,Luigi Manenti,Aung Naing

DOI: https://doi.org/10.1158/1078-0432.ccr-24-2131

IF: 13.801

2024-09-05

Clinical Cancer Research

Abstract:In the original version of this article (1), the analysis presented in the text, figures (Figs. 1 and 2), and supplementary data (Supplementary Fig. S2; Supplementary Table S1) included data from one patient who withdrew consent after enrollment/data collection but prior to analysis. This error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

oncology